Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Upregulation of MICA on high-grade invasive operable breast carcinoma.

Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, Ellis I, Durrant LG.

Cancer Immun. 2007 Oct 22;7:17.

2.

Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction.

Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L.

Neoplasia. 2009 Jul;11(7):662-71.

3.

Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer.

Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W.

Med Oncol. 2011 Jun;28(2):466-74. doi: 10.1007/s12032-010-9480-9. Epub 2010 Mar 31.

PMID:
20354827
4.

Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer.

Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN.

Mod Pathol. 2007 Feb;20(2):183-91. Epub 2007 Jan 5.

5.

Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.

Bandić D, Juretić A, Sarcević B, Separović V, Kujundzić-Tiljak M, Hudolin T, Spagnoli GC, Cović D, Samija M.

Croat Med J. 2006 Feb;47(1):32-41.

6.

Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study.

Kavalar R, Sarcevic B, Spagnoli GC, Separovic V, Samija M, Terracciano L, Heberer M, Juretic A.

Virchows Arch. 2001 Aug;439(2):127-31.

PMID:
11561752
7.

Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.

Zhang R, Zhang H, Wei H, Luo X.

J Environ Pathol Toxicol Oncol. 2000;19(1-2):95-7.

PMID:
10905514
8.
9.

C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.

Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW, Ellis IO.

Br J Cancer. 1996 Jul;74(2):229-33.

10.

Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?

Madjd Z, Durrant LG, Pinder SE, Ellis IO, Ronan J, Lewis S, Rushmere NK, Spendlove I.

Cancer Immunol Immunother. 2005 Feb;54(2):149-56. Epub 2004 Sep 16.

PMID:
15378282
11.

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.

Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R.

J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1.

12.

CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.

Albasri A, Aleskandarany M, Benhasouna A, Powe DG, Ellis IO, Ilyas M, Green AR.

Breast Cancer Res Treat. 2011 Feb;126(1):47-54. doi: 10.1007/s10549-010-0890-3.

PMID:
20390342
13.

Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.

Asch HL, Winston JS, Edge SB, Stomper PC, Asch BB.

Breast Cancer Res Treat. 1999 May;55(2):179-88.

PMID:
10481945
14.

Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival.

Gong YP, Yarrow PM, Carmalt HL, Kwun SY, Kennedy CW, Lin BP, Xing PX, Gillett DJ.

Eur J Surg Oncol. 2007 May;33(4):438-43. Epub 2006 Nov 27.

PMID:
17125961
15.

Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO.

J Pathol. 2006 Mar;208(4):495-506.

PMID:
16429394
16.

Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.

Rakha EA, Pinder SE, Paish EC, Robertson JF, Ellis IO.

J Pathol. 2004 Jul;203(3):754-61.

PMID:
15221934
17.

Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.

Powe DG, Voss MJ, Habashy HO, Zänker KS, Green AR, Ellis IO, Entschladen F.

Breast Cancer Res Treat. 2011 Nov;130(2):457-63. doi: 10.1007/s10549-011-1371-z. Epub 2011 Feb 6.

PMID:
21298476
18.

The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Tang D, Xu S, Zhang Q, Zhao W.

Med Oncol. 2012 Jun;29(2):526-33. doi: 10.1007/s12032-011-9948-2. Epub 2011 Apr 26.

PMID:
21519872
19.

High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas.

Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG.

Breast Cancer Res. 2005;7(5):R780-7. Epub 2005 Jul 28.

20.

Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women.

Selvarajan S, Wong KY, Khoo KS, Bay BH, Tan PH.

Pathology. 2006 Dec;38(6):528-33.

PMID:
17393979
Items per page

Supplemental Content

Write to the Help Desk